Epigenetic modifications in neuropathic pain

Danzhi Luo1,2,*, Xiaohong Li2,*, Simin Tang3, Fuhu Song3, Wenjun Li3, Guiling Xie3, Jinshu Liang3, and Jun Zhou3

Abstract
Neuropathic pain (NP) is a common symptom in many diseases of the somatosensory nervous system, which severely affects the patient’s quality of life. Epigenetics are heritable alterations in gene expression that do not cause permanent changes in the DNA sequence. Epigenetic modifications can affect gene expression and function and can also mediate crosstalk between genes and the environment. Increasing evidence shows that epigenetic modifications, including DNA methylation, histone modification, non-coding RNA, and RNA modification, are involved in the development and maintenance of NP. In this review, we focus on the current knowledge of epigenetic modifications in the development and maintenance of NP. Then, we illustrate different facets of epigenetic modifications that regulate gene expression and their crosstalk. Finally, we discuss the burgeoning evidence supporting the potential of emerging epigenetic therapies, which has been valuable in understanding mechanisms and offers novel and potent targets for NP therapy.

Keywords
transcription, epigenetic modification, neuropathic pain

Date Received: 12 February 2021; Revised 18 September 2021; accepted: 21 September 2021

Introduction
Neuropathic pain (NP) is defined as pain caused by a lesion or disease of the somatosensory nervous system, including unpleasant feelings, such as allodynia and hyperalgesia. These symptoms severely impair the patients’ quality of life, such as sleep disturbances, anxiety, and even depressive symptoms.1,2 Furthermore, NP severely influences approximately 7%–8% of the European population and causes a tremendous medical burden worldwide.3 Because the pathogenetic mechanisms of NP have not been sufficiently elucidated, clinical treatments are not satisfactory. Therefore, it is meaningful to explore the molecular mechanisms of NP.

Epigenetic modifications regulate gene expression without changing the DNA sequence and have a long-lasting influence on the individual when responding to environmental stimuli. The mechanisms are dynamic and reversible by repressing or activating gene expression at gene promoters.4 A few years ago, several reviews have summarized the role of epigenetic modifications in the pathogenesis of NP.5–12 However, knowledge of the epigenetic mechanisms of NP has grown substantially in recent years. Therefore, a more comprehensive review is required to provide new insights to understand the etiology and pathophysiology of NP by summarizing the updated evidence.

In this review, we summarize the latest developments in epigenetic modifications in NP. These findings highlight epigenetic alterations in the development and maintenance of NP, including neuroinflammatory responses, ion channels, unbalanced inhibitory effects, and activation of glial cells. Moreover, we also discuss epigenetic alterations including chemical therapy.

*The first two authors contributed equally to this work.

Corresponding Author:
Jun Zhou, Department of Anesthesiology, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, China.
Email: zhoujun7843@126.com

1Department of Anesthesiology, The First People’s Hospital of Foshan, Foshan, China
2Sun Yet-Sen Memorial Hospital of Sun Yet-Sen University, Guangzhou, China
3Department of Anesthesiology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
modifications to the DNA itself or to DNA-associated proteins (e.g., histones) or noncoding RNAs (ncRNAs) expression or chemical modifications to the RNA and their potential crosstalk. Finally, we suggest that specific epigenetic modifications may provide a novel therapeutic approach for treating refractory diseases.

**General background of epigenetics**

Waddington first put forward the term “epigenetic” in 1942, it refers to heritable changes in phenotype without alteration of the DNA sequence when an organism responds to the environment. Epigenetic modifications are chemical modifications that influence the structure and function of chromatin. Chromatin comprises DNA and histone proteins and provides a scaffold for the packaging of our entire genome, including the heritable material of eukaryotic cells. As the basic critical unit of chromatin, the nucleosome has 147 base pairs of DNA wrapped around a histone octamer, which consist of two dimers each of H2A, H2B, H3, and H4. Epigenetic modifications include DNA methylation, histone modifications, the regulation of noncoding RNA (ncRNA), and RNA modifications.

DNA methylation is the most widely studied epigenetic modification and refers to the covalent binding of a methyl group to the fifth carbon of a cytosine residue, known as 5-methylcytosine (5mC). This process can influence genome stability and repress gene expression. DNA methylation is catalyzed by a family of DNA methyltransferases (DNMTs), which are divided into two categories according to their function: maintenance methyltransferases (DNMT1) and de novo methyltransferases (DNMT3). The primary location of DNA methylation is cytosine-phosphate-guanine (CpG) islands, which are located in the gene promoter. Increased methylation of CpG islands in the gene promoter can influence the stability of chromatin, therefore silencing gene expression. In contrast, DNA demethylation leads to the upregulation of gene expression.

Histone modifications are post-transcriptional modifications (PTMs) to the N-terminal histone tails of nucleosomes that regulate chromatin structure and function. These epigenetic modifications include acetylation, ubiquitination, methylation, phosphorylation, and ADP-ribosylation. Distinct PTM on histones or their combinations play a vital role in gene expression by modulating the access of transcription machinery to DNA. For example, histone acetylation leads to a loose structure that induces gene activation, while histone deacetylation results in gene repression. Histone methylation patterns and their effects on transcription are more complex than acetylation and may induce gene activation and repression depending on the residue that is methylated.

With regard to epigenetic modifications of gene expression, much attention has recently been devoted to ncRNAs that play critical roles in gene regulation. With the rapid development of detection technology in recent years, RNAs have also been epigenetically modified. To date, more than 100 kinds of chemical modifications of RNA have been reported. Of the post-transcriptional gene regulations, the mRNA N6-methyl-adenosine (m6A) is the most studied among RNA modifications. Similar to DNA methylation and histone modifications, m6A methylation is related to the translation and degradation of RNAs (Figure 1).

**Epigenetic modifications in the mechanism of NP**

It is generally accepted that NP is involved in the dysfunction of peripheral and central mechanisms, wherein inflammatory cascades trigger, neuronal firing deregulation, ion channel imbalance, glial activation, and synaptic plasticity, which lead to a lowered pain threshold. For example, epigenetic modifications are involved in synaptic plasticity. Here, we provide an overview of the relationship between epigenetic modification and a common mechanism of NP (Figure 2).

**Neuroinflammatory response**

In the development and maintenance of NP, immune cells, such as mast cells, neutrophils, macrophages, and T lymphocytes, are activated, which release numerous pro-inflammatory mediators, including cytokines, histamine, serotonin, proteases, tumor necrosis factor α (TNFα), interleukins, and chemokines. These mediators trigger an inflammatory cascade and lead to NP. Furthermore, the peripheral immune response may cause ongoing activity associated with central neuroinflammation. Recently, epigenetic modifications have been found to take part in neuroinflammation during NP. Neutrophils and macrophages mediate chemokine that recruit to the injured sciatic nerve (SCN) after partial sciatic nerve ligation. The expression of macrophage inflammatory protein 2 (MIP-2) and C-X-C chemokine receptor type 2 (CXCR2) were epigenetically up-regulated and localized on accumulated neutrophils and macrophages. In the following years, the same research team also showed that epigenetic modification of CC-chemokine ligand (CCL) 2 and CCL3 mediate infiltration of immune cells to elicited NP. They also indicated that vascular endothelial growth factor-A (VEGFA) is epigenetically up-regulated in infiltrating macrophages and neutrophils in injured peripheral nerves. However, neuroinflammation is a defense response that limits tissue damage and restores homeostasis, and anti-inflammatory cytokines also regulate these pain states. There are few studies on epigenetic modification involved in anti-inflammatory cytokines in the pathogenesis of NP. Epigenetic modification of pro-inflammatory and anti-inflammatory factors adds to our understanding of the mechanism of NP.

**Activation of Glial cells**

As the intrinsic immune cells in the CNS, microglia serve protective functions under normal conditions. However,
microglia can be activated to trigger an inflammatory cascade to promote the development of NP.\textsuperscript{35} Epigenetic modification also participates in microglial activation. The regulator of G-protein signaling 10 (RGS10) is one of the critical anti-inflammatory regulators involved in dose-dependent suppression in response to lipopolysaccharide (LPS)-induced microglial activation. Applying HDACi trichostatin A (TSA) and HDAC1 recruitment and H3 histone deacetylation led to gene silencing.\textsuperscript{36} Yadav et al. also showed that epigenetic modification–induced microglia activation contributes to the development of NP. They found that enhancer of zeste homolog-2 (EZH2), a subunit of the polycomb repressive complex 2, leads to gene silencing. After nerve injury, upregulation of the expression of EZH2 leads to an increase in activated microglia, and tri-methylated H3K27 (H3K27me3) is temporally associated with neuroinflammation in the spinal cord of a NP rat model.\textsuperscript{37} Paclitaxel may cause NP, which may continue years after the therapy is stopped,\textsuperscript{38} and is associated with microglia dysregulation. Wu et al.\textsuperscript{39} showed that epigenetics regulates the expression of the purinergic receptor P2X4 in microglia, which causes sensitization of neurons in the dorsal horn to

**Figure 1.** The effects of epigenetic modifications on chromatin structure. Chromatin is primarily composed of nucleosomes, each of which consists of ~147 base pairs of DNA wrapped around a histone octamer. The DNA sequence can be methylated at cytosine residues in a CpG context, termed DNA methylation which represses gene transcription. Histone acetylation (Ac) lead to relaxed chromatin which activate gene expression. While histone methylation facilitate activating or repressing of gene transcription depending on the location of specific lysine in histone. RNA methylation is a form of epigenetic regulation related to the translation and degradation of RNAs.

**Figure 2.** Epigenetic modification in the mechanism of NP. After injury, immune cells, such as mast cells, macrophages and neutrophils are activated and released cytokines (e.g., IL-6, IL-1\(\beta\), TNF-\(\alpha\)) and proinflammatory mediators, which triggers inflammatory cascade. Under epigenetic modifications, the expression of ion channels are downregulated and lead to a lower pain threshold.
induce mechanical allodynia in rats. These studies provided valuable insights into the role of epigenetic modification in microglial activation associated with different models of NP.

Compared with the microglial response, the astrocytic response is delayed, but is sustained for a more extended period. Astrocytes also release pro-inflammatory cytokines and chemokines to respond to harmful stimuli. There is some research showing that epigenetics mediates the activation of astrocytes in NP. CXCR3 is a chemokine receptor. Cxcr3 mRNA and protein expression are significantly epigenetically upregulated in the neurons of the spinal cord in spared nerve injury (SNI) models. In addition, the expression of chemokines, such as CXCL10, one of the ligands of CXCR3, was also increased in both neurons and astrocytes. The epigenetic modification of Cxcr3 gene causes mechanical allodynia and heat hyperalgesia. In addition, Xu et al. showed that the phosphorylation of signal transducers and activators of transcription factor 3 (STAT3) and the acetylation of histone H4 in CXCL12-expressing cells are increased after microtubule-targeted agents–induced NP. The phosphorylation of the transcription factor STAT3 and the acetylation of histone H4 in CXCL12-expressing cells was increased, accompanied by mechanical allodynia. Sanna et al. also found that HDAC1 is associated with the expression of c-Jun N-terminal kinase (JNK) and c-Jun in astrocytes in the spinal dorsal horn; pain symptoms are ameliorated by administration of a selective HDAC1 inhibitor (LG325).

These results have shown that noxious stimuli drive activation of glial cells in epigenetic modifications of NP regulation, and that these changes are associated with pain hypersensitivity under NP conditions.

**Ion channel imbalance**

Ion channel imbalance is usually accompanied by spontaneous ectopic firing and hyperexcitability in the dorsal root ganglion (DRG) and spinal neurons. In addition, ion channel transcriptional and translational changes in gene expression contribute to NP occurrence by increasing neuronal excitability. Accumulating evidence suggests that epigenetic modification involves in ion channel changes after peripheral nerve injury.

Sodium channels play a significant role in the generation and transmission of hypoesthesia and hypoalgesia. The family of sodium channels has five isoforms (Nav1.3, Nav1.6, Nav1.7, Nav1.8, and Nav1.9), all of which have been shown to regulate nociceptive responses. Epigenetic modification was found to participate in NP mechanism. Epigenetic silencing of the Nav1.8 gene in the DRG results in hypoesthesia after nerve injury. It has also been reported that administration of histone deacetylase inhibitors (HDACi) can rescue the downregulation of Nav1.8 in the DRG and ameliorate negative symptoms. However, a previous study indicated that the expression of Nav1.6 is decreased in the early stages of diabetic neuropathic pain (DNP) in rat models induced by streptozotocin, but increases in later periods. Ding et al. also reported that epigenetic upregulation of Nav1.6 gene after lumbar five ventral root transaction–induced NP via TNF-α/STAT3 pathway. These studies provide promising evidence of epigenetic modification in sodium channels expression changes under pain conditions. However, different models of NP may drive different epigenetic changes in the development and maintenance of NP. So, more studies are needed to verify the expression changes in sodium channels in the long run for NP models. These could indicate some potential treatment value for NP.

Nerve injury–induced downregulation of voltage-gated potassium channel in the DRG is another critical factor for neuronal excitability and pain hypersensitivity. Uchida et al. showed that nerve injury leads to gene-mediated epigenetic silencing of Kv4.3 gene through the transcriptional suppressor NRSP in the DRG. Furthermore, Launet et al. demonstrated that euchromatic histone-lysine N-methyltransferase-2 (G9a) induces the transcriptional repression of K+ channels. G9a and DNMT participate in the downregulation of voltage-gated potassium (Kv) channel subunit Kcna2 (encoding Kv1.2) in the DRG. In paclitaxel-induced NP models, decreased expression of K2p1.1 is associated with DNMT3a. Considering that Kv1.2 downregulation contributes to NP genesis; Wu et al. microinjected herpes simplex virus (HSV) to overexpress the Ten-eleven translocation 1 (TET1) protein to help rescue Kv1.2 expression in the ipsilateral DRG. Thus, downregulation of voltage-gated potassium channel may be an endogenous trigger in NP development and maintenance. In this sense, developing methods for reducing NP symptoms with selective epigenetic inhibitors could be a more effective approach.

Voltage-gated calcium channels (Cav) also play a crucial role in transmitting pro-nociceptive neurotransmitters, such as glutamate and substance P, to the spinothalamic tract in the occurrence of peripheral sensitization. Among them, N-type, P-/Q-type, and T-type Cav are mainly expressed in C fibers and are up-regulated in inflammatory or pathological conditions, which are also involved in transmitting pain signals. Evidence has indicated that the expression of voltage-dependent T-type calcium channel 3.2 subunit was regulated by the epigenetic mechanism in pain-related regions in the DRG and dorsal horn of spinal nerve ligation (SNL) model mice. Increasing expression of the voltage-dependent T-type calcium channel 3.2 subunit directly contributes to neuropathic allodynia. However, more profound researches are relatively scarce, and the validation of their functions is not powerful enough.

Transient receptor potential (TRP) channels are non-selective cation channels, and their downregulation also plays an essential role in the NP mechanism. TRPV1, TRPM8, and TRPA1 are the TRP channels that mainly involved in peripheral sensitization; the TRPA1 promoter has been differentially methylated to mediate pain.
sensitivity.71 Norihiko et al. also found that epigenetically increase expression of TRPA1 is associated with burning sensation symptoms in NP.72

G protein-coupled receptor (GPCR) is the largest transmembrane receptor superfamily, which regulates ligand-gated and voltage-gated ion channels. Furthermore, they transmit extracellular signals into cells. GPCR and its ligands play an essential role in NP, mainly including gamma-aminobutyric acid (GABA) receptors, bradykinin receptors, opioid receptors, amine receptors, prostaglandin receptors, and chemokine receptors.73 Emerging studies have shown that epigenetic modification inhibits opioid receptors in pain signal transduction during the development of NP. The analgesic effects of opioid drugs are highly unsatisfactory, in part because opioid receptors are down-regulated by epigenetic silencing of opioid receptor genes in the first-order sensory neurons of DRG, as described below58,74–76 (Figure 4). Altogether, these data indicate that epigenetic modification is a major determinant of pain response in induction and maintenance in NP.

These insights improved our understanding of epigenetic modification in the alteration of ion channel expression during NP pathophysiology. Future studies focused on the detailed mechanisms and functional roles of epigenetic modification are required to develop targeted therapies for NP.

**DNA methylation**

DNA methylation is a crucial epigenetic process that modifies DNA accessibility and regulates gene expression. In recent years, increasing studies have shown that aberrant DNA methylation is associated with the pain mechanism in the brain structure, as well as cortical function.80 DNA methylation of gene promoters is generally associated with gene silencing. Upregulation of DNMT is associated with increased methylation of the MOR gene promoter in the DRG and spinal cord, leading to downregulated opioid receptor expression. This reduced expression usually leads to undesirable opioid analgesic effects in NP.76,81 In addition, DNA methylation represses gene transcription by serving as docking sites for transcription repressors, such as the family of methyl-CpG-binding domain (MBD) proteins, including MBD1–4 and MeCP2.82 It was reported that MBD1 represses gene expression of Oprm1 [encoding mu opioid receptor (MOR)] and Kcnal2 (encoding Kv1.2) in the DRG neurons by recruiting DNMT3a to these two gene promoters.60 (Figure 3) Decreased expression of DNMTs causes DNA demethylation. Emerging studies have shown that the downregulation of DNMT3b and decreased binding of DNMT3b to gene promoters causes hypomethylation. In turn, the transcription factor increased the binding of the specific gene promoter to activate gene expression.83 It was confirmed that hypomethylation leads to the increased expression of the purinergic receptor P2X ligand-gated ion channel 3 (P2X3R) plasticity in DRG neurons, which contribute to NP.84 Jiang et al. also found that chemokine receptor CXCR3 is up-regulated by DNA demethylation and its interaction with CCAAT/enhancer-binding protein α (C/EBPα) aggravates NP. DNA demethylation is either a passive or indirect process in mammalian cells. It is usually mediated by ten-eleven translocation (TET) proteins, including TET1, TET2 and TET3. Accumulating evidence has shown that TET1-triggered transcriptional activation at CpG sites in the promoter contributes to neuron plasticity causing NP.85 Furthermore, TET1-triggered demethylation possibly inhibits DNMT3a from binding to the promoter regions of the gene, exposing a transcription factor binding site, and allowing the transcription factor to bind.83,85 Changes of DNA methylation in the Oprm1 gene and Kcnal2 gene promoter are reversed by TET1-mediated hydroxymethylation, with a concomitant reduction in pain relief.63

These data demonstrate that DNA methylation is critical for the development and/or maintenance of hypersensitivity to pain and this mechanism involves both MBD and reversible DNA methylation. DNA methylation is likely a potential target in neuropathic pain management.

**Histone modifications**

PTM of histone proteins is another significant facet of chromatin structure regulation. Histone modifications are
generally associated with gene expression depending on the target residues. The most common histone modifications are acetylation and methylation.

Histone acetylation leads to gene transcriptional activation, whereas histone deacetylation causes gene repression, catalyzed by histone acetyltransferases (HATs) and reversed by the activity of histone deacetylases (HDACs). Emerging evidence has indicated that enhanced histone acetylation at promoters is associated with increased expression of pain-related genes in NP. 33, 86, 87 The NRSF acts as a transcriptional repressor of genes. Uchida et al. found that hyperacetylation of histone H4, but not of H3, at the NRSF promoter II increases the expression of NRSF, and thus causes increased binding to the neuron-restrictive silencer element within MOR and Nav1.8 genes that negatively influence the expression of MOR and Nav1.8. 50 (Figure 3) However, increasing histone H4 acetylation in the Scn8a promoter (encoding Nav1.6) upregulates Nav1.6 expression in DRG. 53 These results suggest that acetylation at different promoters mediates the ion channel mechanism of NP. Moreover, hyperacetylation of H3K9ac in the promoter region of inflammatory factors and chemokine ligands positively regulates their expression to induce NP. 51–53 Increasing acetylation in histone H3 and H4 at brain-derived neurotrophic factor (BDNF) promoter may influence the balance of the GABAergic and glutamatergic neurotransmissions in the spinal dorsal horn. Therefore, these dysfunctions contribute to thermal hyperalgesia and mechanical allodynia.88 Conversely, increasing acetylation could alleviate the symptoms of NP when administrated with HDACi. 36, 51, 89 Therefore, these studies provided valuable insights into the role of histone modification in the pathophysiological process of NP. Therefore, histone modification may be potential targets for the prevention and/or treatment of NP.

Methyl groups are added to lysine and arginine residues in histone tails in a very specific manner, including mono-, di-, and tri-methylation. Histone methylation and demethylation are catalyzed by histone methyltransferases and histone demethylases, respectively. Histone methylation plays a crucial role in the development of NP. 90 Dimethylation of Lys9 on histone H3 (H3K9me2), which is mediated by G9a, blocks K+ channel gene promoters. 57, 91 In addition, another histone methyltransferase, the suppressor of variegation 3-9 homologs 1 (SUV39H1, H3K9me3), also contributes to nerve injury-induced noiceptive hypersensitivity by inhibiting MOR expression in the DRG. 92 Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine regulating neuropathic hypersensitivity by interacting with and suppressing the descending dopaminergic system. Wang et al. revealed that the recruitment of G9a and SUV39H1 leads to repression of dopamine levels, which may be associated with central sensitization. 93, 94 Furthermore, EZH2, a histone methyltransferase, catalyzes the methylation of histone H3 on K27 (H3K27), resulting in gene silencing. Yadav et al. showed that global levels of EZH2 and H3K27me3 in the L4–5 spinal dorsal horn are upregulated in SNL models. These upregulations may play key roles in the activation of microglia and astrocytes, and the over-production of pro-inflammatory cytokines. 95 Although previous studies have discovered the role of histone H3 lysine methylation, the functional consequences of histone H4 lysine methylation are not well understood. Future studies are needed to explore histone methylation in NP.

NcRNAs

NcRNAs are a cluster of RNAs that do not encode functional proteins and were initially considered to merely regulate gene expression at the posttranscriptional level. Generally, they can be divided into housekeeping ncRNAs and regulatory ncRNAs. RNA that has a regulatory role is mainly divided into two categories based on size: short-chain ncRNAs (including siRNAs, miRNAs, and piRNAs) and long non-coding RNA (IncRNAs). 95, 96 Numerous studies have shown that the epigenetic modification role of miRNAs and IncRNAs regulate the expression of specific pain-related genes in NP.
MiRNAs can negatively regulate gene expression by canonical binding to their target mRNAs or directly interact with proteins. MiRNAs mainly control gene expression by binding to the 3′-untranslated regions (3′ UTR), causing either mRNA degradation or inhibition of protein translation. (Figure 3) For example, Pan et al. found that CXCR4 expression was increased in spinal glial cells of mice with SNL-induced NP. MiR-23a was significantly downregulated by directly binding to 3′ UTR of CXCR4 mRNA. Moreover, overexpression of miR-23a by intrathecal injection of miR-23a mimics or lentivirus reduced spinal CXCR4 attenuated SNL-induced pain hypersensitivity. They also revealed that associated with induction of NOD-like receptor protein 3 (NLRP3) inflammasome, was inhibiting of thioredoxin-interacting protein (TXNIP) reversed pain behavior elicited by SNL, miR-23a knockdown, or CXCR4 overexpression. Also, DNA methylation play epigenetic modification role by regulating the transcription levels of miRNAs. Liu et al. revealed that DNMT3a-mediated epigenetic suppression of miR-214-3p promoter enhanced colony-stimulating factor-1 (CSF1) expression in astrocytes to aggravate neuro-inflammation and neuronal hyperexcitability in SNL model rats. These results suggested that miRNA may potentially serve as novel therapeutic avenues through epigenetic modification in treating NP. In addition, Zhang et al. showed that N6-methyladenosine (m6A) modification took part in miRNA metabolism. In CFA-induced inflammatory pain model, methyltransferase-like 3 (METTL3) regulate pri-miR-365-3p processing by manipulating the binding of microprocessor protein DiGeorge critical region 8 (DGCR8)-dependent manner. This study presents a novel direction that non-coding RNAs are regulated by RNA modification of NP.

LncRNA could interact with target mRNAs and participate in transcriptional silencing through transcription factor that binds to the lncRNA gene promoter. MiRNAs can negatively regulate gene expression by canonical binding to their target mRNAs or directly interact with proteins. MiRNAs mainly control gene expression by binding to the 3′-untranslated regions (3′ UTR), causing either mRNA degradation or inhibition of protein translation. (Figure 3) The expression of Kcna2 antisense RNA (Kcna2 AS RNA) was increased by activating myeloid zinc finger protein 1 (MZF1) after peripheral nerve injury. Upregulation of Kcna2 AS RNA acted as cis-encoded lncRNA and suppressed the expression of the Kcna2 gene. These changes led to downregulation of the K+ channel increasing excitability in DRG neurons and induced NP symptoms. Recent work revealed that a conserved lncRNA named DRG-specifically enriched lncRNA (DS-lncRNA), was downregulated in DRG of CCI model mice. The expression of DS-lncRNA was downregulated by its transcription factor called POU domain, class 4, transcription factor 3 (Pou4f3) to DS-lncRNA gene promoter. Down-regulation of DS-lncRNA increased RALY-triggered Ehmt2 mRNA and its encoding G9a protein expression and correspondingly decreased the expression opioid receptors and Kv1.2 channel, leading to pain hypersensitivities. Rescuing downregulation of DS-lncRNA reverses the G9a-controlled downregulation of opioid receptors and Kv1.2 channel to attenuate pain hypersensitivities. What’s more, lncRNA may regulate neuroinflammation to develop or maintain NP through sponging miRNAs. For instance, lncRNA DGCR5 effectively becomes a miRNA sponge for miR-330-3p to regulate PDCD4 and contributed to mechanical and thermal hyperalgesia through the upregulation of inflammation-correlated biomarkers including interleukin 6 (IL-6), TNF α, and IL-1β in the CCI model. (Figure 3) The identification of pain mechanism-related miRNAs and lncRNAs are needed to explore a therapeutic potential.

However, research regarding this aspect is currently in its infancy, and the mechanisms underlying their role in NP are yet to be elucidated. Thus, future studies focused on the detailed mechanisms, and epigenetic modification roles of ncRNAs are required to develop targeted therapies for NP.

**RNA modification**

Several modifications, such as N6-methyladenosine (m6A), have been detected in mRNA, revealing a new perspective on epi-transcriptomics. Similar to DNA modification and histone modification, m6A is also dynamic and reversible. In molecular mechanisms, m6A affects almost all aspects of mRNA metabolism, including splicing, translation, and stability, as well as miRNA maturation, playing an essential role in a variety of physiological processes. The enzymes involved in RNA modification can be divided into three categories according to their functions. Although accumulating evidence has revealed the biological functions of m6A, which include cell differentiation, immune homeostasis, obesity, and cancer, few pieces of research have focused on the function of m6A in the development and maintenance of NP.

The specific role and molecular mechanism of m6A methylation modification in NP are full of complexity and uncertainty, and further research in this field is still needed in the future. For example, METTL3 is the most studied “writer” m6A methylation enzyme in various systemic diseases. However, different scholars have found that it has opposite changes and effects in the same NP model. Zhang et al. found that the level of spinal m6A modification was significantly increased in Complete Freund’s adjuvant (CFA)-induced chronic inflammatory pain model. At the same time, the expression of methyltransferase-like 3 (METTL3) in the spinal cord was enhanced. The CFA-induced pain behaviors could be prevented and reversed in the conditional knockdown of spinal METTL3 in the spinal cord. However, Pan et al. recently reported the function of METTL3 in CFA-inflammatory pain is the opposite. They found that peripheral inflammation leads to a significant decrease of METTL3 expression in the CFA-induced chronic inflammatory pain model. This decrease correledated with a loss of m6A sites in
Tet1 mRNA. By knocking down or conditionally deleting spinal METTL3 elevated the levels of m6A in Tet1 mRNA and reduced the binding of YTHDF2 to Tet1 mRNA, stabilizing the increased expression of Tet1 mRNA and TET1 protein in spinal cord, resulting in pain hypersensitivity. These opposite findings suggested that m6A enzymes may display distinct changes in different nervous tissues from different types of pain models. Moreover, there may be some m6A enzymes waiting to be unveiled. Furthermore, recent studies have observed that METTL3 protein did not exhibit a significant change in the NP model. These data again indicated that the role and mechanism of METTL3 and other m6A methylase mediated NP are pretty complex, and more evidence is needed to clarify. More recently, Li et al. reported that peripheral nerve injury increases the protein expression of FTO in the injured DRG, which likely contributes to the mechanisms of NP. Mimicking the increased expression of FTO correlates with a loss of m6A sites in Ehmt2 mRNA resulting in upregulation of Ehmt2-encoding G9a protein in SNL and CCI models. And the upregulated expression of G9a protein led to gene silencing, resulting in NP symptoms. (Figure 3) FTO-triggered removal of toll-like receptor4 (Tlr4) mRNA m6A sites may participate in nociceptive hypersensitivities in hemorrhage-induced thalamic pain model. After microinjection of type IV collagenase (Coll IV), the FTO protein levels but not mRNA were time-dependently increased in the ipsilateral thalamus. The upregulation expression of FTO increase erased m6A sites in Tlr4 mRNA in the hemorrhagic thalamus, reducing the binding of YTH domain family protein 2 (YTHDF2, “reader” of m6A-binding protein) to 3'-untranslated regions of Tlr4 mRNA, stabilized the increased expression of Tlr4 mRNA and upregulated TLR4 receptors in the thalamus, resulting in NP symptoms. Therefore, FTO-mediated methylation of m6A participates in hemorrhage-induced thalamic pain by increasing Tlr4 mRNA expression in thalamic neurons.

These discoveries indicate that m6A modification may play a significant role in the development of pathological pain. Until now, the findings of m6A modification have been mainly focused on chronic inflammatory pain. There are few investigations concentrating on the relationship between m6A modification and NP. More studies are needed, which will help us better understand the molecular mechanism of NP.

Crosstalk of epigenetic modifications

Crosstalk between different modifications of gene regulation has been shown to play a key role in epigenetics. It has been reported that DNA methylation and several covalent histone protein post-translational modifications have a highly interactive effect rather than simply acting under harmful stimuli. Histone modification can also positively or negatively affect other modifications. Endogenous DNMT3a could interact with histone methyltransferase SUV39H1 enzymes, leading to gene silence. Moreover, G9a seems to act in concert with SUV39H1. In NP models, Oprm1 gene could be regulated by distinct epigenetic mechanisms. It has been shown that DNMT3a is upregulated and induces downregulation of MOR expression after peripheral nerve injury. Zhang et al. also report that SUV39H1, a histone methyltransferase, is co-expressed with MOR. In the same year, other investigators found that G9a (encoded by Ehmt2), a histone 3 at lysine 9 methyltransferase, also regulates MOR expression in the development of NP. However, it is unclear whether histone

Figure 4. Crosstalk between different epigenetic layers. Chromatin is typically marked by multiple modifications. Crosstalk between these epigenetic marks may work in concert in the process of NP development and progression. (a) Crosstalk enforcing in gene activation. DNA demethylation mediated by Ten-eleven translocation (TET) protein and histone acetylation lead to gene activation. (b) Crosstalk resulting in gene silencing. DNA methylation and histone methylation could lead to gene silencing, and they may have multiple feedback loops to regulate the gene transcription.
methylation is also highly coordinated with DNA methylation through multiple feedback loops (Figure 4). Our understanding of the properties of this epigenome network in NP is in its infancy. RNA m6A modification and epigenetic modifications also have crosstalk in pain models. TET proteins usually mediate DNA demethylation. The m6A methylase METTL3, which is responsible for the increased m6A levels of mRNA, affects mRNA degradation and translation. Pan et al. reported that METTL3 was downregulated, leading to a loss of m6A site in Tet1 mRNA. And the expression of TET1 was upregulated, which contributed to the pain hypersensitivity symptom.112 This investigation reveals the co-occurrences of genetic downregulation.124 However, few studies have investigated the relationship between these epigenetic modifications and how these marks can work in a coordinated state under NP conditions. Further studies are needed to explore the crosstalk occurring among these epigenetic modifications and help us understand of epigenetic mechanisms in NP.

**NP therapies based on epigenetic modifications**

In view of the intrinsic reversibility of epigenetic modifications, chromatin modifiers are potential targets for novel therapeutic strategies against NP.125,126 Several drugs targeting epigenetic modifiers are currently approved for the treatment of various diseases by the Food and Drug Administration and European Medicines Evaluation Agency, including HDACi and DNMT inhibitors. However, most of these inhibitors are being assessed in clinical trials127 (Table 1).

Aberrant hypermethylation induced by the silencing of pain-related genes is commonly associated with the development of NP. The expression of DNMT3a is increased in the DRG and spinal cord of NP model rats with an isoform-nonspecific DNMT inhibitor N-Phthalyl-L-tryptophan (RG108) that upregulates MOR expression and attenuates thermal hyperalgesia in CCI model animals.81 HDACi inhibit the removal of acetyl groups on histone proteins, resulting in increased histone acetylation which provides a more accessible chromatin structure with increased transcription. Increasing interest has been focused on developing HDACi for cancer treatment, as they can modulate gene expression and the activity of numerous non-histone proteins. TSA, valproic acid (VPA), sodium phenyl butyrate, and romidepsin (LAQ-824) belong to the first generation of HDACi and are usually administered intravenously.

In contrast to the first generation of HDACi, second-generation agents, including entinostat (MS-275) and vorinostat (SAHA), can be used as oral formulations.128 A growing number of studies have illustrated that HDACi can be significantly useful in mitigating NP symptoms in rat models (Table 1).43,51,74,89–129,131 Matsushita et al.51 showed that administration of TSA, VPA, and SAHA significantly rescues the expression of Nav1.8, thus restoring C-fiber-related hypoesthesia. Moreover, Uchida et al.89 found that morphine analgesia is restored when treated with HDACi such as TSA and VPA, which are accompanied by an increase in MOR expression.

Intriguingly, some dietary supplements such as S-adenosylmethionine (SAM) and folic acid (FA) which act as critical methyl donors in the CNS can attenuate SNL-induced hypomethylation and NP symptoms.132–134 Some traditional Chinese medicines have been found to ameliorate allodynia and hyperalgesia by reducing the recruitment of transcriptional factors and acetyl-histone H3/acetyl-histone H4 on pain-related genes.135,136 These discoveries have attracted renewed research attention in specific scenarios because of their potential as an analgesic adjuvant in clinical pain management.

However, most of the available epigenetic drugs are non-specific, and their long-term toxicity has not yet been tested. Therefore, epigenetics-based strategies for pain therapy are still in clinical trials. Selectivity of the epigenetic target for treating NP is essential to reduce the risk of adverse effects.

**Future directions**

Despite the overwhelming evidence, the pathological process of NP has not been linked to epigenetic changes. However, there are many critical questions for us to further explore epigenetic processes in NP. First, many of the experimental pain states studied are not commonly seen in clinical practice, while clinical studies in humans are lacking. Second, most of the available data on epigenetics typically use tissues such as the DRG and spinal cord in animal models. Thus, there is an urgent need to find a non-invasive alternative strategy in humans. Third, preclinical studies have focused for the most part on early time points, whereas the clinical symptoms are usually significantly prolonged. How does a primary injury result in long-lasting epigenetic marks, and how are they maintained? Could they be reversed at any time point after an injury? When does interventional therapy better reverse symptoms? However, how epigenetic marks change during the NP process is uncertain. Finally, some epigenetic modifications are preferentially expressed in cell-type–specific conditions.137 The epigenetic inheritance of different cell types and even individual cells is unknown. Thus, future single-cell epigenetic studies will be necessary to deepen our understanding of NP.

Furthermore, neuroimaging data shows that chronic pain corresponds with changes in the amygdala, the anterior
Table 1. Drugs targeting the epigenetic marks in rat's models.

| Drugs               | Model          | Tissue source          | Effect                                                                 | Reference |
|---------------------|----------------|------------------------|------------------------------------------------------------------------|-----------|
| HDACs inhibitors    |                |                        |                                                                        |           |
| TSA                 | SNI            | DRG                    | Recovery of Nav1.8 sodium channel transcription                        | 51        |
|                     |                |                        | Restore MOR downregulation                                             | 89        |
| VPA                 | SNI            | DRG                    | Recovery of Nav1.8 sodium channel transcription                        | 51        |
|                     |                |                        | Restore MOR downregulation                                             | 89        |
| Sodium butyrate     | CCI            | not mentioned          | Repress the levels of TNF-α                                            | 142       |
| MS-275              | Traumatic nerve injury | Spinal cord | Ameliorated mechanical and thermal hypersensitivity                   | 143       |
| SAHA                | SNL            | DRG                    | Recovery of Nav1.8 sodium channel transcription                        | 51        |
|                     |                | Spinal dorsal horn     | Inhibit downregulation of spinal Glutamate transporter-1 (GLT-1)      | 74        |
|                     |                | Spinal cord            | Attenuate neuropathic pain and contributes to autophagy flux in astrocytes and neuronal cells | 144       |
| MGCD0103            | Traumatic nerve injury | Spinal cord | Ameliorated mechanical and thermal hypersensitivity                   | 143       |
| LG325               | SNI            | Spinal cord            | Ameliorated the mechanical allodynia                                  | 145       |
| DNMT inhibitor      |                |                        |                                                                        |           |
| 5-AZA               | CCI            | Lumbar spinal cord     | Attenuate mechanical alldodynia and thermal hyperalgesia              | 146       |
cingulate cortex,138 the prefrontal cortex (PFC), the insular cortex,139 and the nucleus accumbens (NAc).140 These regions display robust interconnections with each other, and directly or indirectly modulate the activity of other pain modulating networks. Tajerian et al. found that global methylation in the prefrontal cortex and amygdala, but not the thalamus or visual cortex were decreased in SNI model after 6 months. It may reverse nerve injury-related reductions in global DNA methylation in the PFC and attenuated hypersensitivity to mechanical and cold stimuli in the environment with higher DNA methylation.141 Further, they also reported that differential methylation in the PFC as well as DNA methylation changes in T cells was associated with peripheral nerve injury, which may be “predictors” of chronic pain.82 Also, Topham et al. identified that pain-related genes had time point-specific differential methylation of individual genes and functional pathways in the PFC.83 Therefore, although current studies on NP epigenetic modification mechanism mainly focus on peripheral nervous system, the above studies suggest that there may be more complex and important epigenetic modification mechanism in central mechanism, which is worthy of further exploration in the future.

Conclusion
Currently, the molecular mechanisms underlying NP and epigenetic modifications are not fully understood. However, evidence increasingly suggests that epigenetic modifications, including DNA methylation, histone modifications, and RNA modification, play critical roles in the development and maintenance of NP by regulating neuroinflammatory responses, activation of glial cells, ion channels, and unbalanced inhibitory receptors. Furthermore, communication between different epigenetic modifiers is still elusive. Fortunately, research into epigenetic modifications in NP is emerging. Epigenomics significantly extends our understanding of NP’s pathogenesis and pathophysiology and offers attractive potential for novel therapeutic approaches. With increasing knowledge of epigenetic modifications and the molecular mechanism of NP, a promising future of effective therapies for NP is not far behind.

Author contributions
Jun Zhou conceptualized the review. Danzhi Luo was a major contributor in writing the manuscript with the help of Xiaohong Li and Simin Tang. Fuhu Song and Wenjun Li. Guiling Xie and Jinshu Liang drew the figures and table. All authors read and approved the final manuscript.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the grant from the National Natural Science Foundation of China (81870879) and the Natural Science Foundation of Guangdong Province(2017A030313534), Guangzhou Key Laboratory of Neuropathic Pain Mechanism at Spinal Cord Level (20210210005).

ORCID iD
Jun Zhou https://orcid.org/0000-0003-1545-8092

References
1. Baron R, Binder A and Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010; 9: 807–819. doi: 10.1016/S1474-4422(10)70143-5.
2. Murnion BP. Neuropathic pain: current definition and review of drug treatment. Aust Prescriber 2018; 41: 60–63. doi: 10.18773/austprescr.2018.022.
3. Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Rev Neurol (Paris) 2019; 175: 16–25. doi: 10.1016/j.neuro.2018.09.016.
4. Berger SL, Kouzarides T, Shiekhattar R, et al. An operational definition of epigenetics. Genes Dev 2009; 23: 781–783. doi: 10.1101/gad.1787609.
5. Wang X, Shen X, Xu Y, et al. The etiological changes of acetylation in peripheral nerve injury-induced neuropathic hypersensitivity. Mol Pain 2018; 14: 1744806918798408. doi: 10.1177/1744806918798408.
6. Penas C and Navarro X. Epigenetic modifications associated to neuroinflammation and neuropathic pain after neural trauma. Front Cell Neurosci 2018; 12: 158. doi: 10.3389/fncel.2018.00158.
7. Odell DW. Epigenetics of pain mediators. Curr Opin Anaesthesiol 2018; 31: 402–406. doi: 10.1097/ACO.0000000000000613.
8. Khandgra RK, Bali A, Jaggi AS, et al. Histone acetylation and histone deacetylation in neuropathic pain: an unresolved puzzle? Eur J Pharmacol 2017; 795: 36–42. doi: 10.1016/j.ejphar.2016.12.001.
9. Ueda H and Uchida H. Epigenetic modification in neuropathic pain. Curr Pharm Des 2015; 21: 849–867.
10. Lutz BM, Bekker A and Yao Y-X. Noncoding RNAs: new players in chronic pain. Anesthesiology 2014; 121: 409–417. doi: 10.1097/ALN.0000000000000265.
11. Liang L, Lutz BM, Bekker A, et al. Epigenetic regulation of chronic pain. Epigenomics 2015; 7: 235–245. doi: 10.2217/epi.14.75.
12. Wu S, Bono J and Yao Y-X. Long noncoding RNA (lncRNA): a target in neuropathic pain. Expert Opin Ther Targets 2019; 23: 15–20. doi: 10.1080/14728222.2019.1550075.
13. Choi S-W and Friso S. Epigenetics: a new bridge between nutrition and health. Adv Nutr 2010; 1: 8–16. doi: 10.3945/an.110.1004.
14. Jirtle RL and Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007; 8: 253–262.
15. Jaenisch R and Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 2003; 33(Suppl): 245–254.
16. Lugner K, Mäder AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. *Nature* 1997; 389: 251–260.
17. Moore LD, Le T and Fan G. DNA methylation and its basic function. *Neuropsychopharmacology* 2013; 38: 23–38. doi: 10.1038/npp.2012.112.
18. Bian E-B, Zong G, Xie Y-S, et al. TET family proteins: new players in gliomas. *J Neurooncol* 2014; 116: 429–435. doi: 10.1007/s10663-013-2387-7.
19. Hyun K, Jeon J, Park K, et al. Writing, erasing and reading histone lysine methylations. *Exp Mol Med* 2017; 49: e324. doi: 10.1038/emm.2017.11.
20. Messner S and Hottiger MO. Histone ADP-ribosylation in DNA repair, replication and transcription. *Trends Cell Biol* 2011; 21: 534–542. doi: 10.1016/j.tcb.2011.06.001.
21. Nowak SJ and Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. *Trends Genet* 2004; 20: 214–220.
22. Li W, Nagaraja S, Delceuve GP, et al. Effects of histone acetylation, ubiquitination and variants on nucleosome stability. *Biochem J* 1993; 296(Pt 3): 737–744.
23. Kouzarides T. Chromatin modifications and their function. *Cell* 2007; 128: 693–705.
24. Cantara WA, Crain PF, Rozenki J, et al. The RNA modification database, RNAMDB: 2011 update. *Nucleic Acids Res* 2011; 39: D195–D201. doi: 10.1093/nar/gkq1028.
25. Niu Y, Zhao X, Wu Y-S, et al. N6-methyl-adenosine (m6A) in RNA: an old modification with a novel epigenetic function. *Genomics Proteomics Bioinformatics* 2013; 11: 8–17. doi: 10.1016/j.gpb.2012.12.002.
26. Baron R. Mechanisms of disease: neuropathic pain—a clinical perspective. *Nat Clin Pract Neurol* 2006; 2: 3–30.
27. Roth TL and Sweat JD. Regulation of chromatin structure in memory formation. *Curr Opin Neurobiol* 2009; 19: 336–342. doi: 10.1016/j.conb.2009.05.011.
28. Calvo M, Dawes JM and Bennett DLH. The role of the immune system in the generation of neuropathic pain. *Lancet Neurol* 2012; 11: 629–642. doi: 10.1016/S1474-4422(12)70134-5.
29. Thacker MA, Clark AK, Marchand F, et al. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. 2007; 105: 838–847. doi: 10.1213/01.ane.0000275190.42912.37.
30. Kiguchi N, Kobayashi Y and Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. *Curr Opin Pharmacol* 2012; 12: 55–61. doi: 10.1016/j.coph.2011.10.007.
31. Kiguchi N, Kobayashi Y, Maeda T, et al. Epigenetic augmentation of the macrophage inflammatory protein 2/C-C-X-C chemokine receptor type 2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain. *J Pharmacol Exp Ther* 2012; 340: 577–587. doi: 10.1124/jpet.111.187724.
32. Kiguchi N, Kobayashi Y, Saika F, et al. Epigenetic upregulation of CCL2 and CCL3 via histone modifications in infiltrating macrophages after peripheral nerve injury. *Cytokine* 2013; 64: 666–672. doi: 10.1016/j.cyto.2013.09.019.
33. Kiguchi N, Kobayashi Y, Kadowaki Y, et al. Vascular endothelial growth factor signaling in injured nerves underlies peripheral sensitization in neuropathic pain. *J Neurochem* 2014; 129: 169–178. doi: 10.1111/jnc.12614.
34. Clark AK, Old EA and Malloci G. Neuronal peroxisome proliferator-activated receptor γ coactivator-1α contributes to spinal cord plasticity in neuropathic pain. *Neuropharmacology* 2011; 21: 534–542. doi: 10.1016/j.jpain.2018.10.007.
35. Alqinyah M, Maganti N, Ali MW, et al. Regulator of G protein signaling 10 (rgs10) expression is transcriptionally silenced in activated microglia by histone deacetylase activity. *Mol Pharmacol* 2017; 91: 197–207. doi: 10.1124/mol.116.106963.
36. Ewertz M, Qvortrup C and Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. *Acta Oncol* 2015; 54: 587–591. doi: 10.3109/0284186X.2014.995775.
37. Wu J, Hocevar M, Bie B, et al. Cannabinoid type 2 receptor system modulates paclitaxel-induced microglial dysregulation and central sensitization in rats. *J Pain* 2019; 20: 501–514. doi: 10.1016/j.jpain.2018.10.007.
38. Ewertz M, Qvortrup C and Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. *Acta Oncol* 2015; 54: 587–591. doi: 10.3109/0284186X.2014.995775.
39. Kiguchi N, Kobayashi Y, Maeda T, et al. Epigenetic augmentation of the macrophage inflammatory protein 2/C-C-X-C chemokine receptor type 2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain. *J Pharmacol Exp Ther* 2012; 340: 577–587. doi: 10.1124/jpet.111.187724.
40. Echeverry S, Shi XQ and Zhang J. Characterization of cell proliferation in rat spinal cord following peripheral nerve injury and the relationship with neuropathic pain. *Pain* 2008; 135: 37–47.
41. Jiang B-C, He L-N, Wu X-B, et al. Promoted interaction of C/EBPα with demethylated Cxcr3 gene promoter contributes to neuropathic pain in mice. *The J Neurosci* 2017; 37: 685–700. doi: 10.1523/jneurosci.2262-16.2016.
42. Xu T, Zhang X-L, Ou-Yang H-D, et al. Epigenetic upregulation of CXCL12 expression mediates antitubulin chemotherapeutics-induced neuropathic pain. *Pain* 2017; 158: 637–648. doi: 10.1097/j.1526-4637.2016.105971.
43. Sanna MD and Galeotti N. The HDAC1/c-JUN complex is essential in the promotion of nerve injury-induced neuropathic pain through JNK signaling. *Eur J Pharmacol* 2018; 825: 99–106. doi: 10.1016/j.ejphar.2018.02.034.
44. Latremoliere A and Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. *J Pain* 2009; 10: 895–926. doi: 10.1016/j.jpain.2009.06.012.
45. Denk F and Stephen. Chronic pain: emerging evidence for the involvement of epigenetics. 2012; 73: 435–444. doi: 10.1016/j.uneron.2012.01.012.
46. Dib-Hajj SD, Black JA and Waxman SG. Voltage-gated sodium channels: therapeutic targets for pain. *Pain Medicine (Malden, Mass)* 2009; 10: 1260–1269. doi: 10.1111/j.1526-4637.2009.00719.x.
47. Xie W, Strong JA, Ye L, et al. Knockdown of sodium channel NaV1.6 blocks mechanical pain and abnormal bursting activity.
of afferent neurons in inflamed sensory ganglia. Pain 2013; 154: 1170–1180. doi: 10.1016/j.pain.2013.02.027.
48. Garrison SR, Weyer AD, Barabas ME, et al. A gain-of-function voltage-gated sodium channel 1.8 mutation drives intense hyperexcitability of A- and C-fiber neurons. Pain 2014; 155: 896–905. doi: 10.1016/j.pain.2014.01.012.
49. Thériault O and Chahine M. Correlation of the electrophysiological profiles and sodium channel transcripts of individual rat dorsal root ganglia neurons. Front Cellular Neuroscience 2014; 8: 285. doi: 10.3389/fncel.2014.00285.
50. Uchida H, Ma L and Ueda H. Epigenetic gene silencing underlies C-fiber dysfunctions in neuropathic pain. 2010; 30: 4806–4814. doi: 10.1523/jneurosci.5541-09.2010.
51. Matsushita Y, Araki K, Oi O, et al. HDAC inhibitors restore C-fibre sensitivity in experimental neuropathic pain model. Br J Pharmacol 2013; 170: 991–998. doi: 10.1111/bph.12366.
52. Ren Y-S, Qian N-S, Tang Y, et al. Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes. Brain Res Bull 2012; 87: 244–249. doi: 10.1016/j.brainresbull.2011.10.015.
53. Ding H-H, Zhang S-B, Lv Y-Y, et al. TNF-α/STAT3 pathway epigenetically upregulates Nav1.6 expression in DRG and contributes to neuropathic pain induced by L5-VRT. J Neuroinflammation 2019; 16: 29. doi: 10.1186/s12974-019-1421-8.
54. Pollema-Mays SL, Centeno MV, Ashford CJ, et al. Expression of background potassium channels in rat DRG is cell-specific and down-regulated in a neuropathic pain model. Mol Cell Neurosci 2013; 57: 1–9. doi: 10.1016/j.mcn.2013.08.002.
55. Mao Q, Yuan J, Ming X, et al. Role of dorsal root ganglion K2p1.1 in peripheral nerve injury-induced neuropathic pain. Mol Pain 2017; 13: 1744806917701135. doi: 10.1177/1744806917701135.
56. Uchida H, Sasaki K, Ma L, et al. Neuron-restrictive silencer factor causes epigenetic silencing of Kv4.3 gene after peripheral nerve injury. Neuroscience 2010; 166: 1–4. doi: 10.1016/j.neuroscience.2009.12.021.
57. Laumet G, Garriga J, Chen S-R, et al. G9a is essential for epigenetic silencing of K+ channel genes in acute-to-chronic pain transition. Nat Neurosci 2015; 18: 1746–1755. doi: 10.1038/nn.4165.
58. Liang L, Gu X, Zhao J-Y, et al. G9a participates in nerve injury-induced Kcnma2 downregulation in primary sensory neurons. Scientific Reports 2016; 6: 37704. doi: 10.1038/srep37704.
59. Zhao J-Y, Liang L, Gu X, et al. DNA methyltransferase DNMT3a contributes to neuropathic pain by repressing Kcma2 in primary afferent neurons. Nat Commun 2017; 8: 14712. doi: 10.1038/ncomms14712.
60. Mo K, Wu S, Gu X, et al. MBD1 contributes to the genesis of acute pain and neuropathic pain by epigenetic silencing of Oprm1 and Kcnma2 genes in primary sensory neurons. The J Neurosci 2018; 38: 9883–9899. doi: 10.1523/jneurosci.0880-18.2018.
61. Sun L, Gu X, Pan Z, et al. Contribution of DNMT1 to neuropathic pain genesis partially through epigenetically repressing in primary afferent neurons. J Neurosci 2019; 39: 6595–6607. doi: 10.1523/JNEUROSCI.0695-19.2019.
62. Mao Q, Wu S, Gu X, et al. DNMT3a-triggered downregulation of K.1.1 gene in primary sensory neurons contributes to paclitaxel-induced neuropathic pain. Int J Cancer 2019; 145: 2122–2134. doi: 10.1002/ijc.32155.
63. Wu Q, Wei G, Ji F, et al. TET1 overexpression mitigates neuropathic pain through rescuing the expression of μ-opioid receptor and Kv1.2 in the primary sensory neurons. Neurotherapeutics 2019; 16: 491–504. doi: 10.1007/s13311-018-00689-x.
64. Zamponi GW, Lewis RJ, Todorovic SM, et al. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev 2009; 60: 84–89. doi: 10.1016/j.brainresrev.2008.12.021.
65. Newton RA, Bingham S, Case PC, et al. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res 2001; 95: 1–8.
66. Chapman SR. Neuropathic pain: role of voltage-dependent calcium channels. Reg Anesth Pain Med 2000; 25: 283–285.
67. Lai C-Y, Hsieh M-C, Ho Y-C, et al. Growth arrest and DNA-damage-inducible Protein 45β-mediated DNA Demethylation of Voltage-dependent T-type Calcium Channel 3.2 subunit enhances neuropathic allodynia after nerve injury in rats. Anesthesiology 2017; 126: 1077–1095. doi: 10.1097/ALN.0000000000001610.
68. Frederick J, Buck ME, Matson DJ, et al. Increased TRPA1, TRPM8, and TRPV2 expression in dorsal root ganglia by nerve injury. Biochem Biophys Res Commun 2005; 358: 1058–1064.
69. Binder A, May D, Baron R, et al. Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS ONE 2011; 6: e17387. doi: 10.1371/journal.pone.0017387.
70. Basso L and Allier C. Transient receptor potential channels in neuropathic pain. Curr Opin Pharmacol 2017; 32: 9–15. doi: 10.1016/j.coph.2016.10.002.
71. Bell JT, Loomis AK, Butcher LM, et al. Differential methylation of the TRPA1 promoter in pain sensitivity. Nat Communications 2014; 5: 2978. doi: 10.1038/ncomms3978.
72. Sukenaga N, Ikeda-Miyagawa Y, Tanada D, et al. Correlation Between DNA Methylation of TRPA1 and chronic pain states in human whole blood cells. Pain Med 2016; 17: 1906–1910.
73. Thompson MD, Burnham WM and Cole DEC. The G protein-coupled receptors: pharmacogenetics and disease. Crit Rev Clin Lab Sci 2005; 42: 311–392.
74. Cui S-S, Lu R, Zhang H, et al. Suberylanilide hydroxamic acid prevents downregulation of spinal glutamate transporter-1 and attenuates spinal nerve ligation-induced neuropathic pain behavior. Neuroreport 2016; 27: 427–434. doi: 10.1097/WNR.0000000000000558.
75. Zhang J, Liang L, Miao X, et al. Contribution of the suppressor of variegation 3-9 homolog 1 in dorsal root ganglia and spinal cord dorsal horn to nerve injury–induced nociceptive hyper-sensitivity. Anesthesiology 2016; 125: 765–778. doi: 10.1097/ALN.0000000000001261.
76. Sun L, Zhao J-Y, Gu X, et al. Nerve injury-induced epigenetic silencing of opioid receptors controlled by DNMT3a in primaryafferent neurons. *Pain* 2017; 158: 1153–1165. doi: 10.1097/j.pain.0000000000000894.

77. Moore KA, Kohno T, Karchewski LA, et al. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. *J Neurosci* 2002; 22: 6724–6731.

78. Jembrek MJ and Vlainic J. GABA receptors: pharmacological potential and pitfalls. *Curr Pharm Des* 2015; 21: 4943–4959.

79. Wang Y, Lin Z-P, Zheng H-Z, et al. Abnormal DNA methylation in the lumbar spinal cord following chronic constriction injury in rats. *Neurosci Letters* 2016; 610: 1–5. doi: 10.1016/j.neulet.2015.10.048.

80. Tajerian M, Alvarado S, Millecamps M, et al. Peripheral nerve injury is associated with chronic, reversible changes in global DNA methylation in the mouse prefrontal cortex. *PLoS ONE* 2013; 8: e55259. doi: 10.1371/journal.pone.0055259.

81. Shao C, Gao Y, Jin D, et al. DNMT3a methylation in neuropathic pain. *J Pain Res* 2017; 10: 2253–2262. doi: 10.2147/jpr.131065.

82. Turek-Plewa J, Jagodziński PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. *Cell Mol Biol Lett* 2005; 10: 631–647.

83. Jiang B-C, Zhang W-W, Yang T, et al. Demethylation of G-protein-coupled receptor 151 promoter facilitates the binding of krippel-like factor 5 and enhances neuropathic pain after nerve injury in mice. *The J Neurosci* 2018; 38: 10535–10551. doi. 10.1523/jneurosci.0702-18.2018.

84. Zhang H-H, Hu J, Zhou Y-L, et al. Promoted interaction of Krüppel-like factor 5 and enhances neuropathic pain after nerve injury in mice. *Diabetes* 2014; 63: 1116–1121. doi:10.2337/db15-0138.

85. Liang L and Tao Y-X. Expression of acetyl-histone H4 in dorsal root ganglion and spinal dorsal horn mediates neuropathic pain in rats. *Scientific Rep* 2016; 6: 37411. doi: 10.1038/srep37411.

86. Liang L and Tao Y-X. Expression of acetyl-histone H3 and acetyl-histone H4 in dorsal root ganglion and spinal dorsal horn in rat chronic pain models. *Life Sci* 2018; 211: 182–188. doi: 10.1016/j.lfs.2018.09.029.

87. Li K, Zhao G-Q, Li L-Y, et al. Epigenetic upregulation of Cdk5 in the dorsal horn contributes to neuropathic pain in rats. *Neuroreport* 2014; 25: 1116–1121. doi: 10.1097/WNR.0000000000000237.

88. Uchida H, Matsushita Y and Ueda H. Epigenetic regulation of BDNF expression in the primary sensory neurons after peripheral nerve injury: implications in the development of neuropathic pain. *Neuroscience* 2013; 240: 147–154. doi: 10.1016/j.neuroscience.2013.02.053.

89. Uchida H, Matsushita Y, Araki K, et al. Histone deacetylase inhibitors relieve morphine resistance in neuropathic pain after peripheral nerve injury. *J Pharmacol Sci* 2015; 128: 208–211. doi: 10.1016/j.jphs.2015.07.040.

90. Zhang Y, Lautem G, Chen S-R, et al. Pannexin-1 up-regulation in the dorsal root ganglion contributes to neuropathic pain development. *J Biol Chem* 2015; 290: 14647–14655. doi: 10.1074/jbc.M115.650218.

91. Liang L, Gu X, Zhao J-Y, et al. G9a participates in nerve injury-induced KcnA2 downregulation in primary sensory neurons. 2016; 6: 37704. doi: 10.1038/srep37704.

92. Zhang J, Liang L, Miao X, et al. Contribution of the suppressor of variegation 3-9 homolog 1 in dorsal root ganglia and spinal cord dorsal horn to nerve injury–induced nociceptive hypersensitivity. 2016; 125: 765–778. doi: 10.1097/ALN.00000000000001261.

93. Wang N, Shen X, Bao S, et al. Dopaminergic inhibition by G9a/Glp complex on tyrosine hydroxylase in nerve injury-induced hypersensitivity. 2016; 16: 1744806916663731. doi: 10.1177/1744806916663731.

94. Wang X, Ma S, Wu H, et al. Macrophage migration inhibitory factor mediates peripheral nerve injury-induced hypersensitivity by curbing dopaminergic descending inhibition. *Exp Mol Med* 2018; 50: e445. doi: 10.1038/emm.2017.271.

95. Kopp F and Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. *Cell* 2018; 172: 393–407. doi: 10.1016/j.cell.2018.01.011.

96. Ha M and Kim VN. Regulation of microRNA biogenesis. *Nat Rev Mol Cell Biol* 2014; 15: 509–524. doi: 10.1038/nrm3838.

97. Liu C, Shan Q, Gu P, et al. miRNA-23a/CXCR4 regulates neuropathic pain via directly targeting TXNIP/NLRP3 inflammasome axis. *J Neuroinflammation* 2018; 15: 29. doi: 10.1186/s12974-018-1073-0.

98. Liu L, Xu D, Wang T, et al. Epigenetic reduction of miR-214-3p upregulates astrocytic colony-stimulating factor-1 and contributes to neuropathic pain induced by nerve injury. *Pain* 2020; 161: 96–108. doi: 10.1016/j.pain.2020.04.016.

99. Wang C, Wang Y, Peng Y, et al. METTL3 regulates inflammatory pain by modulating mA-dependent pri-miR-365-3p processing. *FASEB J* 2020; 34: 122–132. doi: 10.1096/fj.201901555R.

100. Zhao X, Tang Z, Zhang H, et al. A long noncoding RNA contributes to neuropathic pain by silencing KcnA2 in primary afferent neurons. *Nat Neuroscience* 2013; 16: 1024–1031. doi: 10.1038/nn.3438.

101. Pan Z, Du S, Wang K, et al. Downregulation of a dorsal root ganglion-specifically enriched long noncoding RNA is required for neuropathic pain by negatively regulating RALLY-triggered Ehmt2 expression. *Adv Sci* 2021; 8: 2004515. doi: 10.1002/ads.20204515.

102. Zhou J, Fan Y and Chen H. Analyses of long non-coding RNA and mRNA profiles in the spinal cord of rats using RNA sequencing during the progression of neuropathic pain in an SNI model. *RNA Biol* 2017; 14: 1810–1826. doi: 10.1080/15476286.2017.1371400.

103. Xia L-X, Ke C and Lu J-M. NEAT1 contributes to neuropathic pain development through targeting miR-381/HMGB1 axis in CCI rat models. *J Cell Physiol* 2018; 233: 7103–7111. doi: 10.1002/jcp.26526.

104. Yan X-T, Lu J-M, Wang Y, et al. XIST accelerates neuropathic pain progression through regulation of miR-150 and ZEB1 in...
105. Peng C, Zhang C, Su Z, et al. DGCR5 attenuates neuropathic pain through splicing miR-330-3p and regulating PDCD4 in CCI rat models. J Cell Physiol 2018; 233: 6098–6106. doi: 10.1002/jcp.26453.

106. Wu J, Wang C and Ding H. LncRNA MALAT1 promotes neuropathic pain progression through the miR-154-5p/AQP9 axis in CCI rat models. Mol Med Rep 2020; 21: 291–303. doi: 10.3892/mmr.2019.10829.

107. Shi H, Wei J and He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell 2019; 74: 640–650. doi: 10.1016/j.molcel.2019.04.025.

108. Meyer KD and Jaffrey SR. The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nat Rev Mol Cell Biol 2014; 15: 313–326. doi: 10.1038/nrm3785.

109. Frye M, Harada BT, Behm M, et al. RNA modifications modulate gene expression during development. Science 2018; 361: 1346–1349. doi: 10.1126/science.aau1646.

110. Du K, Zhang L, Lee T, et al. mRNA methylation controls neural development and is involved in human diseases. Mol Neurobiol 2019; 56: 1596–1606. doi: 10.1007/s12035-018-1138-1.

111. Lan Q, Liu PY, Haase J, et al. The critical role of RNA m4A ethylation in cancer. Cancer Res 2019; 79: 1285–1292. doi: 10.1158/0008-5472.CAN-18-2965.

112. Pan Z, Zhang Q, Liu X, et al. Mettl3 contributes to inflammatory pain by targeting TET1 in YTHDF2-dependent manner. Pain 2021; 162: 1960–1976.

113. Ma L, Huang Y, Zhang F, et al. MMP24 contributes to neuropathic pain in an FTO-dependent manner in the spinal cord neurons. Front Pharmacol 2021; 12: 673831. doi: 10.3389/fphar.2021.673831.

114. Li Y, Guo X, Sun L, et al. N-Methyladenosine demethylase FTO contributes to neuropathic pain by stabilizing G9a expression in primary sensory neurons. Adv Sci (Weinh) 2020; 7: 1902402. doi: 10.1002/advs.201902402.

115. Zheng B-X, Malik A, Xiong M, et al. Nerve trauma-caused downregulation of opioid receptors in primaryafferent neurons: Molecular mechanisms and potential managements. Exp Neurol 2021; 337: 10512. doi: 10.1016/j.expneurol.2020.113572.

116. Fu G, Du S, Huang T, et al. FTO (fat-mass and obesity-associated protein) participates in hemorrhage-induced thalamic pain by stabilizing toll-like receptor 4 expression in thalamic neurons. Stroke 2021; 52: 2393–2403. doi: 10.1161/STROKEAHA.121.034173.

117. Jeltsch A, Broche J and Bashirlykov P. Molecular processes connecting DNA methylation patterns with DNA methyltransferases and histone modifications in mammalian genomes. Genes (Basel) 2018; 9: 566. doi: 10.3390/genes9100566.

118. Fu K, Bonora G and Pellegrini M. Interactions between core histone marks and DNA methyltransferases predict DNA methylation patterns observed in human cells and tissues. Epigenetics 2020; 15: 272–282. doi: 10.1080/15592294.2019.1666649.

119. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007; 447: 407–412.

120. Li B, Carey M and Workman JL. The role of chromatin during transcription. Cell 2007; 128: 707–719.

121. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011; 21: 381–395. doi: 10.1038/cr.2011.22.

122. Fuks F, Hurd PJ, Deplus R, et al. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 2003; 31: 2305–2312.

123. Zhang T, Cooper S and Brockdorff N. The interplay of histone modifications - writers that read. EMBO Rep 2015; 16: 1467–1481. doi: 10.15252/embr.201540945.

124. Albik S and Tao Y-X. Emerging role of RNA m6A modifications in chronic pain. Pain 2021; 162: 1897–1898. doi: 10.1097/j. pain.0000000000002219.

125. Doehring A, Geisslinger G and Lötsch J. Epigenetics in pain and analgesia: an imminent research field. Eur J Pain 2011; 15: 11–16. doi: 10.1016/j.ejpain.2010.06.004.

126. Géranton SM. Targeting epigenetic mechanisms for pain relief. Curr Opin Pharmacol 2012; 12: 35–41. doi: 10.1016/j.coph.2011.10.012.

127. Dawson MA and Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012; 150: 12–27. doi: 10.1016/j.cell.2012.06.013.

128. Kim H-J and Bae S-C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3: 166–179.

129. Chiuchio S, Copani A, Zammataro M, et al. Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci 2010; 31: 153–160. doi: 10.1016/j.tips.2009.12.003.

130. Zhao Y and Wu T. Histone deacetylase inhibition inhibits brachial plexus avulsion-induced neuropathic pain. Muscle Nerve 2018; 58: 434–440. doi: 10.1002/mus.26160.

131. Tao W, Zhou W, Wang Y, et al. Histone deacetylase inhibitor-induced emergence of synaptic 6-opioid receptors and behavioral antinociception in persistent neuropathic pain. Neurosciencen 2016; 339: 54–63. doi: 10.1016/j.neuroscience.2016.09.015.

132. Garriga J, Laumet G, Chen S-R, et al. Nerve injury-induced chronic pain is associated with persistent DNA methylation reprogramming in dorsal root ganglion. J Neurosci 2018; 38: 6090–6109. doi: 10.1523/JNEUROSCI.2616-17.2018.

133. Miranpuri GS, Meethal SV, Sampene E, et al. Folic acid modulates matrix metalloproteinase-2 expression, alleviates neuropathic pain, and improves functional recovery in spinal cord-injured rats. Ann Neurosci 2017; 24: 74–81. doi: 10.1159/000475896.

134. Grégoire S, Millecamps M, Naso L, et al. Therapeutic benefits of the methyl donor s-adenosylmethionine on nerve injury-induced mechanical hypersensitivity and cognitive impairment in mice. Pain 2017; 158: 802–810. doi: 10.1097/j.pain. 0000000000000811.

135. Zhu X, Li Q, Chang R, et al. Curcumin alleviates neuropathic pain by inhibiting p300/CRE histone acetyltransferase activity-regulated expression of BDNF and Cox-2 in a rat model. 2014; 9: 091303. doi: 10.1371/journal.pone.091303.

136. Cheng C-H, Lee K-C, Chien C-C, et al. Baiacalin ameliorates neuropathic pain by suppressing HDAC1 expression in the
spinal cord of spinal nerve ligation rats. 2014; 113: 513–520. doi: 10.1016/j.jfma.2013.04.007.

137. Pollema-Mays SL, Centeno MV, Apkarian AV, et al. Expression of DNA methyltransferases in adult dorsal root ganglia is cell-type specific and up regulated in a rodent model of neuropathic pain. Front Cellular Neuroscience 2014; 8: 217. doi: 10.3389/fncel.2014.00217.

138. Toyoda H, Zhao M-G and Zhuo M. Enhanced quantal release of excitatory transmitter in anterior cingulate cortex of adult mice with chronic pain. Mol Pain 2009; 5: 4. doi: 10.1186/1744-8069-5-4.

139. Schweinhardt P and Bushnell MC. Pain imaging in health and disease–how far have we come? J Clin Invest 2010; 120: 3788–3797. doi: 10.1172/JCI43498.

140. Nasca C, Xenos D, Barone Y, et al. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A 2013; 110: 4804–4809. doi: 10.1073/pnas.1216100110.

141. Gonçalves L, Silva R, Pinto-Ribeiro F, et al. Neuropathic pain is associated with depressive behaviour and induces neuroplasticity in the amygdala of the rat. Exp Neurol 2008; 213: 48–56. doi: 10.1016/j.expneurol.2008.04.043.

142. Kukkar A and Singh N, Jaggi AS. Attenuation of neuropathic pain by sodium butyrate in an experimental model of chronic constriction injury in rats. J Formos Med Assoc 2014; 113: 921–928. doi: 10.1016/j.jfma.2013.05.013.

143. Denk F, Huang W, Sidders B, et al. HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain. Pain 2013; 154: 1668–1679. doi: 10.1016/j.pain.2013.05.021.

144. Feng X-L, Deng H-B, Wang Z-G, et al. Suberoylanilide hydroxamic acid triggers autophagy by influencing the mTOR pathway in the spinal dorsal horn in a rat neuropathic pain model. Neurochem Res 2019; 44: 450–464. doi: 10.1007/s11064-018-2698-1.

145. Sanna MD, Guandalini L, Romanelli MN, et al. The new HDAC1 inhibitor LG325 ameliorates neuropathic pain in a mouse model. Pharmacol Biochem Behav 2017; 160: 70–75. doi: 10.1016/j.pbb.2017.08.006.

146. Wang Y, Liu C, Guo Q-L, et al. Intrathecal 5-azacytidine inhibits global DNA methylation and methyl-CpG-binding protein 2 expression and alleviates neuropathic pain in rats following chronic constriction injury. Brain Res 2011; 1418: 64–69. doi: 10.1016/j.brainres.2011.08.040.